- ILLUMINATE 204 Data selected as subject of a poster discussion session to be held on
The company plans to hold an investor/analyst event at the ASCO Annual Meeting on
Additionally, the Phase 3 ILLUMINATE 301 trial in anti-PD-1 refractory melanoma has opened to enrollment during the first quarter of 2018.
Accepted Abstracts for
|Title (1):||A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT)
injection of the TLR9 agonist IMO-2125 (IMO) in combination with
ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.
|Poster Display Session:||Melanoma/Skin Cancers|
|Date:||June 4, 2018, 1:15 – 4:45 PM CT|
|Presenter:||Adi Diab, MD, MD Anderson Cancer Center|
|Poster Discussion Session:||Melanoma Skin Cancers|
|Date:||June 4, 2018 4:45 – 6:00 PM CT|
|Title (2):||Preliminary safety of deep/visceral (D/V) image guided (IG) intratumoral
injection (ITI) of IMO-2125.
|Author:||Hani Babiker, MD, University of Arizona Cancer Center|
|Title (3):||Right tumor, right time: Systematic methodology for fiducial marker
placement to achieve reliable and reproducible image guided (IG)
delivery of intratumoral immunotherapy into deep/visceral (D/V) lesions
and target-lesion imaging follow-up.
|Author:||Gregory John Woodhead, MD, PhD, University of Arizona Cancer Center|
About Tilsotolimod (IMO-2125)
Tilsotolimod is a TLR 9 agonist that received Fast Track Designation from the
The Illuminate 204 study (2125-204) is for patients who have metastatic melanoma for whom treatment with an anti-PD-1 drug like Keytruda® (pembrolizumab) or Opdivo® (nivolumab) has failed. Melanoma is the most dangerous type of skin cancer. When it is metastatic, it means that the melanoma has spread to different parts of the body. Illuminate 204 is a multi-center, two-arm Phase 1/2 study that tests the safety and effectiveness of tilsotolimod in combination with either ipilimumab (Yervoy®) or pembrolizumab (Keytruda®) for the treatment of patients with PD-1 refractory metastatic melanoma.
For additional details about Illuminate 204, please go to clinicaltrials.gov and search for study identifier NCT02644967.
The Illuminate 301 study (2125-MEL-301) is for patients who have metastatic melanoma for whom treatment with an anti-PD-1 drug like Keytruda® (pembrolizumab) or Opdivo® (nivolumab) has failed. Illuminate 301 is a multi-center, randomized Phase 3 study that compares the effectiveness and safety between two treatment groups: IMO-2125 combined with ipilimumab (Yervoy®) versus ipilimumab given alone.
For additional details about Illuminate 301, please go to clinicaltrials.gov and search for study identifier NCT03445533.
About Metastatic Melanoma
Melanoma is a type of skin cancer that begins in a type of skin cell called melanocytes. As is the case in many forms of cancer, melanoma becomes more difficult to treat once the disease has spread beyond the skin to other parts of the body such as the lymphatic system (metastatic disease). Because melanoma occurs in younger individuals, the years of life lost to melanoma are also disproportionately high when compared with other cancers. Although melanoma is a rare form of skin cancer, it comprises over 75% of skin cancer deaths.
Harnessing the approach of the earliest researchers in immunotherapy and the company’s vast experience in developing proprietary immunology platforms, Idera’s lead development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the company's strategy, future operations, collaborations, intellectual property, cash resources, financial position, future revenues, projected costs, prospects, clinical trials, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Idera Pharmaceuticals Contact:
VP, Investor Relations
Phone (484) 639-7235
Source: Idera Pharmaceuticals, Inc.